Reduction of insulin/insulin-like growth factor 1 (IGF1) signaling (IIS) extends the lifespan of various species. So far, several longevity mouse models have been developed containing mutations related to growth signaling deficiency by targeting growth hormone (GH), IGF1, IGF1 receptor, insulin receptor, and insulin receptor substrate. In addition, p70 ribosomal protein S6 kinase 1 (S6K1) knockout leads to lifespan extension. S6K1 encodes an important kinase in the regulation of cell growth. S6K1 is regulated by mechanistic target of rapamycin (mTOR) complex 1. The v-myc myelocytomatosis viral oncogene homolog (MYC)-deficient mice also exhibits a longevity phenotype. The gene expression profiles of these mice models have been measured to identify their longevity mechanisms. Here, we summarize our knowledge of long-lived mouse models related to growth and discuss phenotypic characteristics, including organ-specific gene expression patterns. [BMB Reports 2019; 52(1): 70-85]

INTRODUCTION

Insulin/insulin-like growth factor 1 (IGF1) signaling (IIS) is evolutionarily conserved from worms to human (1). Decreased IIS has been related to longevity in an evolutionarily conserved manner (2), showing consistent results in major model organisms, including worms (1), flies (3), and mice (4). Human centenarian studies have revealed that variations are positioned at proteins involved in the IIS system (5). In rodents, IGF1 is mainly produced from the liver by stimulation of growth hormone (GH, also known as somatotropin) secreted from the somatotrophs in the anterior pituitary (6). Circulating IGF1 binds to insulin/IGF1 receptors on the cell membrane of organs and primarily promotes tissue growth at an early developmental stage. Insulin, the other binding substrate of the insulin/IGF1 receptors, is produced by pancreatic β cells in response to postprandial nutrient influx (7). Insulin reduces high blood glucose levels after meals to maintain glucose homeostasis by suppressing glucose production in the liver, and stimulating glucose uptake in muscle and in fat by activation of their carbohydrate metabolism (8). This GH-IIS endocrine cascade axis is an excellent model for aging research to interpret how growth relates to metabolism. Insulin and IGF1 activate the IIS pathway through the insulin receptor (IR), IGF1 receptor (IGF1R), insulin receptor substrate 1 (IRS1), IRS2, phosphoinositide 3-kinase (PI3K), and protein kinase B (Akt) (7). Consequently, the IIS pathway changes gene expression through transcription factors, such as forkhead box O (FOXOs) and the v-myc myelocytomatosis viral oncogene homolog (MYC) (Fig. 1). In this review, we discuss physiological (Table 1) and global gene expression (Table 2) analyses in mice genetically modified to reduce GH-IIS axis in an effort to elucidate the longevity mechanism.

GH SIGNAL-DEFICIENT MICE

Several dwarf mouse models have been introduced in the aging research field, including Snell (disruption of the Pou-domain transcription factor [Pit-1]), Ames (defect of the homeobox protein prophet of Pit-1 [Prop 1−/−]), and Little (a missense mutation at growth hormone-releasing hormone receptor [Ghrhr−/−]). The Snell and Ames mice are hypopituitary dwarf deficient in GH, prolactin (PRL), and thyroid-stimulating hormone (TSH). These dwarf mice have been shown to live 37-68% longer than their wild-type (WT) littermates (9-11). The Little mice are another GH-deficient model. It was generated by deletion of the Ghrhr gene and the mice have been shown to live 23-25% longer than their WT littermates (9). The Snell, Ames, and Little GH-deficient mice commonly have small body sizes and high adiposity, with low IGF1 levels.

The mouse GH receptor (Ghr) gene was disrupted (Ghr−/−) to create a mouse model for human Laron syndrome (12). The GHR−/− mouse has been shown to have very low (less than 10% of normal) plasma IGF1 level and severely reduced IGF binding protein 3 (IGFBP3) level (13). A GH receptor antagonist (GHA) transgenic (Tg) mouse was generated by a single amino acid substitution in GH (14). A 50% reduction in plasma IGF1 has been reported in GHA Tg mice, compared to their WT littermates. Both GHR−/− and GHA Tg mice have been shown
Fig. 1. GH-IIS axis and hepatic gene expression patterns in long-lived mice. Components of the GH-IIS axis impact on hepatic gene expression and affect longevity. We divided GH-IIS axis genetically-modified mouse models into four groups: 1) GH signal-deficient mice with mutation at genes affecting GH production and GH signaling, 2) IGF1-reduced mice with homozygous and heterozygous mutation at genes involved in IGF1 production, including IGF1R and IR, 3) IRS-deficient mice including homozygous and heterozygous mutations of Irs1 and Irs2, and 4) mTORC1- and MYC-reduced mice with homozygous and heterozygous mutations for reduction of mTORC1 levels, lack of S6K1, p66Shc deficiency, and lower MYC levels. The target genes for long-lived mouse models are written in bolded red. Downstream liver gene expression patterns for longevity are displayed on the bottom panel.

Growth signaling and longevity
Seung-Soo Kim and Cheol-Koo Lee

http://bmbreports.org

GLOBAL HEPATIC GENE EXPRESSION ALTERATION IN GH-RELATED MODEL MICE

GH stimulates its primary target, the liver, causing it to produce IGF1. A number of microarray analyses have identified genes for longevity mechanism using liver tissues taken from Ames and Snell dwarf mice (27-34). Although early studies identified only a few genes (27, 28), later studies using high-density oligonucleotide microarrays that can detect >12,000 RNA transcripts identified hundreds of differentially expressed genes (DEGs) as candidates in the aging mechanism. Papaconstantinou et al. reported hepatic DEGs using young (3-6 months of age) Snell male mice. Major down-regulated DEGs included IGF1, Insulin like growth factor binding protein acid labile subunit (Igfals), and Forkhead box C1 (Foxc1).
| Mice models                   | Key Physiology                  | Long-lived models                                      | Average Lifespan (%) | Body weight (%) | Body fat | Insulin sensitivity | Tumor incidence | Stress resistance | Plasma GH | Plasma IGF1 | Plasma glucose | References                  |
|----------------------------|--------------------------------|--------------------------------------------------------|----------------------|----------------|----------|---------------------|----------------|------------------|-----------|-------------|----------------|----------------------------|
| Snell (Pou1f1−/−)           | GH, PRL and TSH deficiency     | F + 15 M + 28 (11718806) F and M + 38 (15699523)       | ↓ (25-33)            | ↑             | ↑        | ↑                   | ↓              | ↓               | ↓         | ↓           | ↑             | 16577229 1371619            |
| Ames (Prop1−/−)              | GH, PRL and TSH deficiency     | F + 16 M + 26 (8900272) F and M + 37 (11719795)        | ↓ (33)               | ↑             | ↑        | ↑                   | ↓             | ↓               | ↓         | ↓           | ↑             | 11718806 15699523           |
| Little (Ghrhr−/−)            | GH deficiency                  | F + 19 M + 23 (11371619) F + 38 M + 55 (10875265)      | ↓ (50-67)            | ↑             | ↑        | ↑                   | ↓             | ↓               | ↓         | ↓           | ↑             | 1270976 1371619             |
| Ghr−/−                       | GH resistance                 | F + 25 M + 16 (12933651) F + 30 M + 30 (16682650)      | ↓ (41-50)            | ↑             | ↑        | ↑                   | ↓             | ↓               | ↓         | ↑ or ↓       | ↑             | 10875265 12933651          |
| Fgf21 Tg−/−                  | GH resistance                 | F + 40 M + 30 (23066506)                                 | ↓ (60)               | ↔             | ↑        | ↑                   | ↑             | ↓               | ↑         | ↑           | ↓             | 18585098 23066506           |
| Li-Igf1−/−                   | IGF1 reduction 75-85%         | F + 16 (21799924)                                       | ↓ (75-100)           | ↓             | ↓        | ↑                   | ↑             | ↓               | ↓         | ↑           | ↔             | 10359843 21799924          |
| Heart Igf1 Tg−/−             | IGF1 excessed                 | F + 24 M + 30 (17681037) F + 29 M + 24 (20351075)      | ↔ (100)              | ?             | ?        | ?                   | ?             | ?               | ↑         | ↑           | ↔             | 17973971 17681037          |
| Pappa−/−                     | IGF1 reduced                  | F + 38 M + 38 (17681037) F + 29 M + 24 (20351075)      | ↓ (40)              | ↔             | ↑        | ↑                   | ↑             | ↓               | ↓         | ↓           | ↔             | 14973274 17681037          |
| Klotho Tg                    | IIS inhibition                | F + 19 M + 31 (16123266) F + 19 M + 30 (16123266)      | ↔ (100)              | ?             | ?        | ↑                   | ↑             | ↓               | ↑         | ↓           | ↔             | 16123266                 |
| Igfr1−/−                     | IGF1 resistance               | F + 35 M + 01 (12438226) F + 33 M + 33 (12438226)      | ↓ (90)              | ?             | ↓        | ↔                   | ↑, F ↑ M       | ↑               | ↑         | ↑           | ↔             | 12483226 22132081          |
| Brain IGF1 R1−/− × F1r−/−    | Brain IIS reduction           | F + 8 M + 3 (18959478) F + 10 M + 0 (18959478)        | ↓ (90-92)            | ↑             | ↓        | ↑                   | ↑             | ↓               | ↑         | ↑           | ↔             | 18959478                 |
| Ins1−/−                      | Insulin resistance            | F + 24 M + 24 (20351075) F + 29 M + 24 (20351075)      | ↓ (70)              | ↓             | ↓        | ?                   | ?             | ?               | ↑         | ↑           | ↔             | 12110165 12543978          |
| Ins2−/−                      | Irs2 reduced                  | F + 7 M + 17 (17641201) F + 6 M + 17 (17641201)        | ↔ (100)              | ↑ or ↔        | ↑         | ↑                   | ↑             | ↓               | ↑         | ↑           | ↔             | 17641201 17928362          |
| Brain Irs2−/− × Brain Irs2−/−| Irs2 reduced                  | F + 4 M + 01 (17641201) F + 2 M + 01 (17641201)        | ↔ (100)              | ↑             | ↑         | ↑                   | ↑             | ↑               | ↑         | ↑           | ↔             | 17641201                 |
| mTORC1−/− : mls8−/− × S6K1−/−| mTORC1 reduction 50%          | F + 24 M + 24 (22461615) F + 25 M + 24 (22461615)      | ↔ (100)              | ↑             | ↑        | ↑                   | ↑             | ↑               | ↑         | ↑           | ↔             | 22461615                 |
| S6K1−/− × p66hc−/− × p66hc−/−| IRS inhibition, S6K1 inhibition| F + 20 M + 20 (19797661) F + 21 M + 20 (19797661)      | ↓ (48)              | ↓             | ↓        | ↑                   | ↑             | ↑               | ↑         | ↑           | ↔             | 19797661                 |
| Myc−/−                       | IGF1 reduction and MYC-regulated genes | F + 21 M + 11 (25619689) F + 21 M + 11 (25619689) | ↓ (81)              | ↔             | ↑         | ↑                   | ↑             | ↑               | ↑         | ↑           | ↔             | 25619689                 |
| Mice models          | Key Physiology          | Average Lifespan (%) | Body weight (%) | Body fat | Insulin sensitivity | Tumor incidence | Stress resistance | Plasma GH | Plasma IGF1 | Plasma glucose | References        |
|---------------------|-------------------------|----------------------|-----------------|----------|---------------------|-----------------|------------------|-----------|-------------|----------------|------------------|
| Normal or short-lived models |
| GHA Tg              | GH resistance           | NS (12933651)        | ↓ (55-70)       | ↑         | ↑                   | ↓               | ?                | ↓         | ↓ or ↔     | ↓ or ↔         | 1791834 11487276 |
|                     |                         |                      |                 |          |                     |                 |                  |           |            |                | 12933651 15231300 |
| Bovine GH Tg        | GH excessed             | M-45 (14583653)      | ↑ (200)         | ↓         | ↓                   | ↑               | ↑                | ↑         | ↑         | ↑ or ↔        | 1791834 11701438 |
|                     |                         |                      |                 |          |                     |                 |                  |           |            |                | 14583653 15231300 18948397 |
| LID                 | 75% reduced IGF1        | M-? (22421704)       | ↔ (100)         | ↑         | ↓                   | ↓               | ?                | ↑         | ↓         | ↔            | 10377413 11344415 22421704 |
| KL−/−*              | IIS activation, growth retardation | 60.7 days* (9363890) | ↓ (44-47)      | ?         | ↓                   | ↓               | ?                | ↑ or ↔   | ↑ or ↔     | ↑ or ↔         | 9363890 |
| Ins2−/−*            | Ins2 deletion           | F-26 M-84 (9495343)  | ↓ (90)          | ?         | ↓                   | ?               | ?                | ↑         | ↑         | ↑              | 9495343 |

* New added or updated mice models in this review.
↑ up-regulated; ↓ down-regulated; ↔ no difference; ?, no data available.
*Median lifespan. *Significant at censored lifespan data before week 130-135. *No lifespan data for control.
NS, not significant.
Table 2. Transcriptome studies from long-lived mouse models for the GH/IGF axis

| Genotype       | Publication                      | Design (age: month) | Study Focus          | Sex | Background         | Tissue | Platform (probesets) | DEG number (statistical criteria) |
|----------------|---------------------------------|---------------------|----------------------|-----|--------------------|--------|----------------------|----------------------------------|
| GH-deficient   |                                 |                     |                      |     |                    |        |                      |                                  |
| Snell          | Dozmorov et al. 2004 113867646   | WT vs Snell (6)     | Systemic GH effects  | Male| (DW × C3H)F1       | Liver  | (2,352) Clontech Mouse Atlas 1.2 array | 17 (t-test FDR < 0.05) |
| Snell          | Boylston et al. 2004 15379852    | WT vs Snell (3,5, 24-28) | Systemic GH effects  | Male| C3H/Het × DW/J F1 or C3Dw | Liver  | (12,422) Affymetrix MG U74Av2 array | > 50 (t-test, P < 0.05 and FC > 2) |
| Snell          | Papaconstantinou et al. 2005 15888324 | Snell ctrl (+/?), vs Snell (3,6, 20-28) | IGF-1 axis protein levels | Male| C3H/Het × DW/J F1 or C3Dw | Liver  | (12,422) Affymetrix MG U74Av2 array | 17 (t-test P < 0.05) |
| Snell          | Boylston et al. 2006 19943135    | Snell ctrl (+/?), vs Snell (4-6, 24-26) | Systemic GH effects  | Male| C3H/Het × DW/J F1 or C3Dw | Liver  | (12,422) Affymetrix MG U74Av2 array | 205 (t-test FDR < 0.05) |
| Ames           | Dozmorov et al. 2001 11213270    | WT vs Ames (5, 13, 22) | Systemic GH effects  |     |                    | Liver  | (265) early version of spotting array | 13 (t-test P < 0.01) |
| Ames           | Tsuchiya et al. 2004 15039484    | WT vs Ames (2)      | Systemic GH effects  | Female|                    | Liver  | (12,422) Affymetrix MG U74Av2 array | 212 (two-way ANOVA FDR < 0.05) |
| Ames           | Amador-Noguez et al. 2004 15569359 | WT littermate vs Ames (3, 6, 12, 24) | Systemic GH effects against wt aging patterns | Male| C57Bl/6 | Liver | (> 14,000) Affymetrix MOE340A array | 122 (t-test Bonferroni < 0.05 and FC > 2) |
| Ames           | Boylston et al. 2006 19943135    | Ames ctrl (+/?), vs Ames (4-6, 12-14, 24-27) | Systemic GH effects  | Male| C57Bl/6 | Liver | (> 34,000) Affymetrix MG U74Av2 array | 785 (t-test FDR < 0.05) |
| Little         | Amador-Noguez et al. 2004 15569359 | WT vs Little mice (3,6,12,24) | Systemic GH effects against wt aging patterns | Male| C57Bl/6 | Liver | (> 14,000) Affymetrix MOE340A array | 104 (t-test Bonferroni < 0.05 and FC > 2) |
| bGH Tg         | Olsson et al. 2003 12736163      | WT vs bGH-Tg (6)    | Systemic GH effects  | Male|                    | Liver  | (11,000) Affymetrix mouse 11ka and 11kb arrays | 45 (difference call parameter 3-4) |
| Ghr            | Miller et al. 2002 12403853      | WT vs Ghr −/− (8,9) | Systemic GH effects  |     |                    | Liver  | (2,352) Clontech Mouse Atlas 1.2 array | 10 (t-test FDR < 0.05) |
| Ghr −/−        | Rowland et al. 2005 15601831     | WT vs Ghr −/− (1,4) | Systemic GH effects  | Male| B6.C3H-6T | Liver | (12,422) Affymetrix MG U74Av2 array | 398 (t-test P < 0.0005 and FC > 1.5) |
| GHR-569,       | Rowland et al. 2005 15601831     | WT vs GHR-569, GHR-391 (1,4) | Systemic STAT5 effects | Male| 129/SvJ | Liver | (12,422) Affymetrix MG U74Av2 array | 20 (t-test P < 0.0005 and FC > 1.5) |
| GHR-391        |                                 |                     |                      |     |                    |        |                      |                                  |
| GHR-391        | Barclay et al. 2011 21084450     | WT vs GHR-391 −/− (6) | STAT5-mediated effects | Male| C57Bl/6J | Liver | (46,632) Illumina MouseWG-6 v1.1 array | 55 common genes out of 466 (t-test P < 0.05, FC > 2) |
| GHR −/−        | Stout et al. 2015 26436954       | WT vs GHR −/− (6)   | Systemic GH effects on WAT and BAT | ? | ? | WAT and BAT | (28,853) Affymetrix GeneChip Mouse Gene 1.0 ST Array | 346 in SubQ WAT, 319 in PERI WAT, 192 in EPI WAT, 280 in BAT (t-test FDR < 0.05 and FC > 1.5) |
| Genotype | Publication | Design (age: month) | Study Focus | Sex | Background | Tissue | Platform (probesets) | DEG number (statistical criteria) |
|----------|-------------|---------------------|-------------|-----|------------|--------|--------------------|----------------------------------|
| Ghr−/−  | Chang et al. 2016 27064376 | WT vs Ghr−/− (3-7.4-2) | Systemic GH effects on IncRNA and mRNA | Male and Female | C57Bl/6 | Liver | (25,376 transcript, 31,423 IncRNAs, 3,1000 miRNAs) Agilent Mouse LncRNA Array v2.0 | 3,442 IncRNAs, 1,750 mRNAs in female, 2,642 IncRNAs, 1,489 miRNAs, 57 miRNAs in male (FC ≥ 2) |
| Fgf21-Tg | Zhang et al. 2012 23066506 | WT vs FGF21−/− (3) | Systemic FGF21 effects | Male | C57Bl/6 | Liver, WAT, Muscle | (> 25,600 Illumina mouseRef-8 v2.0 BeadChip) | 33 in liver, 8 in muscle, 22 in fat (t-test FDR < 0.1 and FC > 2) |

Sex-specific liver gene expression

| Genotype | Publication | Design (age: month) | Study Focus | Sex | Background | Tissue | Platform (probesets) | DEG number (statistical criteria) |
|----------|-------------|---------------------|-------------|-----|------------|--------|--------------------|----------------------------------|
| Ames     | Amador-Noguez et al. 2005 15925325 | WT vs Ames (3-6) | Sexual dimorphism of GH effects | Male vs Female | C57Bl/6 | Liver | (> 14,000) Affymetrix MOE430A array | 381 sex-independent, 110 sex-dependent (two-way ANOVA P < 0.001 and FC > 1.5) |
| STAT5b−/− | Clodfelter et al. 2006 16469768 | WT vs STAT5b−/− (1.8-2.1) | Sexual dimorphism of STAT5b effects | Male vs Female | ? | Liver | (23,574) Agilent Sosetta/Merck Mouse TOE 75k array | 85 in female (t-test P < 0.05, FC > 1.5) |
| STAT5a−/− | Clodfelter et al. 2007 17536022 | WT vs STAT5a−/− (1.4-2.1) | Sexual dimorphism of STAT5a effects | Male vs Female | 129 x BlackSwiss | Liver | (23,574) Agilent Sosetta/Merck Mouse TOE 75k array | 769 in male, 461 in female (t-test P < 0.05, FC > 1.5) |

IGF1- and IIS-reduced mice

| Genotype | Publication | Design (age: month) | Study Focus | Sex | Background | Tissue | Platform (probesets) | DEG number (statistical criteria) |
|----------|-------------|---------------------|-------------|-----|------------|--------|--------------------|----------------------------------|
| FIR−/−   | Bluher et al. 2004 15131119 | WT vs WAT (3) | Fat-specific IR & Adipocyte size effect | Male | C57Bl/6 x 129/Sv | WAT | (12,488) Affymetrix MG-U74Av2 array | 48 for adipocyte size, 63 for IR signaling (t-test P < 0.001 and 1-p value > 2.5E-10) |
| FIR−/−   | Katic et al. 2007 18001293 | WT vs FIR−/− (6, 18, 30:36) | Fat-specific IR effect | Male | 129sv/C57Bl6/J | WAT | (22,690) Affymetrix mouse 430A array | 11 (ANOVA P < 0.01) |
| Ins1−/−  | Selman et al. 2008 17928362 | WT vs Ins1−/− (2.6, 15, 22) | Systemic IIS effects | Female | C57Bl/6 | Liver | (> 34,000) Affymetrix MG 430 2.0 array | (t-test P < 0.05) |
| Ins1−/−  | Page et al. 2018 29779018 | WT vs Ins1−/− (15) | Systemic IIS effects | Female | C57Bl/6 | Liver, Muscle, Brain, WAT | RNA-sequencing by Thermo Fisher Ion Proton system | 124 (101, specific) in liver, 185 (137) in muscle, 111 (94) in brain, 345 (319) in WAT (t-test FDR < 0.1) |

mTORC1- and MYC-reduced mice

| Genotype | Publication | Design (age: month) | Study Focus | Sex | Background | Tissue | Platform (probesets) | DEG number (statistical criteria) |
|----------|-------------|---------------------|-------------|-----|------------|--------|--------------------|----------------------------------|
| S6K1−/−  | Selman et al. 2009 19797661 | WT vs S6K1−/− (20) | Systemic S6K1 effect | Female | C57Bl/6 | Liver, Muscle, WAT | (> 38,000) Affymetrix MG 430 2.0 array | 1,843 in liver, 2,309 in muscle, 1,970 in WAT (q value < 0.01) |
| p66Shc−/− | Tomilov et al. 2010 19892704 | WT vs p66Shc−/− (3, 12) | Systemic p66Shc effect | Male and Female | ? | Liver, Spleen, Lungs, WAT, peritoneal macrophage | (> 38,000) Affymetrix MG 430 2.0 array | 752 top 250 genes (t-test P < 0.05) |
| Myc−/−   | Hofmann et al. 2015 25619689 | WT vs Myc−/− (5, 24) | Systemic MYC effects | Male | C57Bl/6 6NCrl | Liver, Muscle, WAT | (28,853) Affymetrix Mouse 1.0 Gene ST arrays | 307 in liver, 160 in muscle, 412 in WAT (t-test FDR < 0.05 and FC > 1.5) |
Major up-regulated DEGs included Igf2, Igf1 receptor (Igf1r), Igf binding protein 1 (Igfbp1), Igfbp2, Igfbp3, Irs1, Irs2, and Fossp1 (33).

Tsuchiya et al. identified 212 DEGs (FDR < 0.05) in Ames dwarf mice livers, including two genes encoding Forkhead transcription factors (Foxa3 was up-regulated and Foxa2 was down-regulated), as well as up-regulated xenobiotic metabolism and glutathione synthesis genes (31). Another transcriptome study using Ames dwarf mice livers showed hundreds of genes affected by aging. Amador-Noguez et al. reported that 357 DEGs (P < 0.0001) were associated with age progression (3, 6, 12, and 24 months old) in Ames dwarf male mice. In particular, they found up-regulated genes for cholesterol and steroid biosynthesis (29). They also found an increase in Igf1 transcript levels during aging, as well as progressive decreases of Igfbp1 and Igfbp2 transcript levels (29). Boyston et al. identified 49 DEGs (FDR < 0.05) in livers from both Snell and Ames dwarf male mice, at both young and old ages. They used 4-6 month old (young age) and 24-26 month old (old age) for Snell mice, and 4-6 month old, 12-14 month old (middle age) and 24-27 month old for Ames mice. Among the DEGs, they found up-regulated genes encoding cytochrome P450 (CYP), and Flavin containing monoxygenase 3 (Fmo3). Fmo3 encodes a flavin adenine dinucleotide (FAD)-dependent monoxygenase that metabolizes various sulfur- and nitrogen-containing metabolites (35). There was a down-regulation of Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 5 (Hsd3b5). The Hsd3b5 gene plays important roles in the biosynthesis of various steroid hormones (36). The Hydroxyaciac oxidase 2 (Hao2) gene, which encodes a flavin mononucleotide (FMN)-dependent peroxisomal 2-hydroxy acid oxidase for long chain 2-hydroxy acid substrates was up-regulated (37).

Using Ames and Little male mice, 547 common DEGs (P < 0.001) were identified in liver during the aging process in 3, 6, 12, and 24 month old mice (29). Gene ontology (GO) analysis showed that the up-regulated DEGs are involved in the oxidative stress response, xenobiotic metabolism, mitochondrial respiration and β-oxidation, and the down-regulated DEGs are involved in humoral defense, including the complement system regulatory genes.

Using GHR−/− male mice (1.5 months old), 330 DEGs were identified in the liver. Up-regulated DEGs were those for β-oxidation, oxidative phosphorylation (OXPHOS), tricarboxylic acid (TCA) cycle, and factors for transcription and translation. Serine protease inhibitors were down-regulated DEGs (38). Using two GHR site-specific truncated mutants, GHR-569 and GHR-391 mouse strains, phosphorylation status of STAT5 was either decreased or removed in the liver by bGH treatment, respectively (38). GHR-STAT5 signaling was severely weakened in these two mutant mice. Using these two mutant mice, 20 common DEGs (P < 0.0005 and FC > 1.5) were identified in the liver (38). Down-regulated DEGs included Igf1, Igfals, Epidermal growth factor receptor (Egfr), and Hsd3b5. Up-regulated DEGs included Sulforotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 2 (Sult2a2), Angiogenin, ribonuclease, RNase A family, 5 (Ang), and Hao2. Sult2a2 and Ang play roles in the sulfation of hydroxysteroid and host defense, respectively. Up-regulated DEGs also included several genes encoding CYPs and glutathione S-transferases (GSTs) (38). Additional studies of GHR-391 and GHR−/− mice showed that the loss of GHR-STAT5 signaling caused intracellular lipid accumulation and steatosis by increasing phosphorylation of STAT1 and STAT3 proteins (39). A recent study using young GHR−/− male and female mice (16-18 weeks old) showed a transcript regulatory network for steroid hormone biosynthesis in the liver, composed of several long-noncoding RNA and microRNAs (40).

Using 3 month old young Fgf21 Tg male mice, transcriptome analysis identified 33, 22, and 8 DEGs (FDR < 0.1 and FC > 2) from the liver, epididymal white adipose tissue (WAT), and gastrocnemius, respectively (21). The hepatic DEGs included up-regulation of Fgf21, Fmo3, Cytochrome P450, family 2, subfamily b, polypeptide 9 (Cyp2b9), and Metallothionein 1 (Mt1) genes; and down-regulation of Igfals, Hsd3b5, Major urinary protein 4 (Mup4), Glutathione S-transferase, pi 1 (Gstpi), and Sterol carrier protein 2 (Scp2) genes (21). The authors compared the hepatic DEGs they found to 43 common hepatic DEGs from the four long-lived dwarf strains, including Snell, Ames, Little, and GHR−/− mice (41). They found eight overlapped genes, including down-regulated Igfals, Hairy and enhancer of split 6 (Hes6), Aminolevulinic acid synthase 2, erythroid (Alas2), Cyp4a12b, Mup4, Serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 12 (Serpin12), and Hsd3b5; as well as up-regulated Fmo3 (21). Although only a small number of DEGs were found in the liver, white fat and skeletal muscle, the young long-lived Fgf21 Tg male mice showed dramatic phenotypical and physiological changes, including low body weight and low levels of plasma Igf-1, insulin, and glucose, as well as high levels of plasma ketone bodies (21).

META-ANALYSIS OF TRANSCRIPTOME FROM GH SIGNAL-DEFICIENT MICE

Swindell performed a meta-analysis using microarray data obtained from livers of Snell, Ames, Little, and GHR−/− mice. DEG selection (mean difference significance test P < 0.05) revealed different DEG numbers among these mice models. The GHR−/− mice showed the smallest number of DEGs (46 DEGs), and other mice strains showed hundreds of DEGs: 151-316 DEGs from Snell, 400-987 DEGs from Ames, and 475-650 DEGs from Little. The range in number of DEGs was due to different ages of the mice. The results revealed that these mice strains shared strong down-regulation of Igf1 (41). Comparison of gene expression across these four dwarf mice identified 13 common DEGs, including 3 up-regulated genes:
Hao3, Sult2a2, and Serine peptidease inhibitor, Kazal type 3 (Spink3). It also identified 10 down-regulated genes: Mup3, Mup4, Igf1, Igfals, Egfr, Socs2, Leukemia inhibitory factor receptor alpha (Lifr), Carboxylesterase 3A (Ces3a: also known as Es31), Hsd3b5, and Kidney expressed gene 1 (Keg1) (41). One down-regulated common DEG, Lifr, has not yet been studied for its role in aging and longevity. The Lifr gene encodes a receptor for the leukemia inhibitory factor (LIF) cytokine that affects various biological functions, including stem cell self-renewal, the reproductive process, and bone modeling (42). Interestingly, LIF can affect the anterior pituitary gland to decrease somatotroph, lactotroph and gonadotroph cells (43).

Malfunction of genes for DNA repair, such as Excision repair cross-complementing rodent repair deficiency, complementation group 1 (Ercc1), Ercc6 (also known as CSB), and Xeroderma pigmentosum, complementation group A (Xpa), caused progeroid syndromes in DNA repair-deficient mouse models. Csbnm/m::Xpa−/− showed a severe phenotype, Ercc1−/− showed intermediate, Csbnm/m showed mild, and Xpa−/− showed no phenotype in mouse models (44, 45). Interestingly, Csbnm/m::Xpa−/− progeria mice showed reduction of serum IGF1 and glucose levels, and suppression of the GH-IIS axis (45). Schumacher et al. performed a meta-analysis to compare transcriptome data between progeria mice (Csbnm/m::Xpa−/−, Ercc1−/−, Ercc1−/−−, Csbnm/m and Xpa−/−) and long-lived dwarf mice (Snell, Ames and Little) (46). Strikingly, the hepatic transcriptome data showed a high correlation (r > 0.7) in gene expression patterns. They found a trend for down-regulation of genes involved in the GH-IIS axis, oxidative metabolism, and energy metabolism, and an up-regulation trend in genes involved in the stress response (46).

### SEXUAL DIMORPHISM OF TRANSCRIPTOME IN LIVER

At the GH signal-deficient models including Snell, Ames, GHR−/−, and Fgf21 Tg mice, female models showed a greater difference of lifespan than male models (Table 1). GH secretion from the pituitary gland is stimulated by sex-steroids (47), and there is a different pattern of secretion between males and females (48). This indicates sexual dimorphism, including global gene expression in the liver (49-51).

Amador-Noguez et al. studied sexual dimorphism in the liver using 126 DEGs (P < 0.001 and FC > 1.5) between female and male WT mice (32). They found that genes involved in fatty acid biosynthesis and steroid hormone metabolism, especially Hsd3b2, Hsd3b3, Hsd3b5, and Hsd3b6 encoding a hydroxysteroid dehydrogenase, were down-regulated in female WT mice. In contrast, genes for metabolic enzymes including Fmo3, metallothioneins, and peroxisomal acyl-CoA thioesterases were up-regulated in female WT mice. Particularly, xenobiotic metabolizing CYP genes were dominantly up-regulated in female WT mice. Interestingly, sex-specific expression of those 126 DEGs in WT were almost completely lost in Ames dwarf mice (32). The complete loss of sexual dimorphism in the long-lived Ames dwarf mice might reflect a reduction of reproduction that needs a costly physiological investment. This may be a potentially important determinant of the extended longevity of these mice.

JAK2 phosphorylates GHR serving as a docking site for STAT transcription factors in GH signaling in the liver. There are seven mouse STAT proteins, and STAT5a and STAT5b proteins play key roles in sex-specific hepatic gene expression (52, 53). In young (1.4-1.8 month old) mice, STAT5a regulated 23% (89 out of 393 genes) of the sex-specific gene expression, including down-regulation of Y-linked Ddx3y, Eif2s3y, and Jarid1d genes, up-regulation of Sult (sulfotransferase) genes, and both up- and down-regulation of CYP genes in female livers (53). STAT5b regulated 90% (767 out of 950 genes) of down-regulated genes and 61% (461 out of 753) of up-regulated genes in females (52). STAT5b-dependent sex-specific genes were primarily involved in oxidative metabolism, tryptophan and fatty acid metabolism, steroid metabolism, signaling, xenobiotic metabolism, and serine protease inhibition (52).

### IGF1 AND IIS-REDUCED MICE

The major proportion of circulating IGF1 is produced by the liver (54). In the liver, by the binding of GH, GHR signaling transmits through JAK-STAT, and consequently activates IGF1 transcription, production, and secretion into the blood stream (6). Circulating IGF1 bioavailability is mediated by IGF binding proteins (IGFBPs). Deletion of the Pappa gene encoding a metalloproteinase, Papayllisin-1 that cleaves IGF1 bound to IGFBP4 decreased bioavailability of IGF1 (55). Indeed, Pappa−/− mice showed 40% smaller body mass, lower cancer incidence, and a 24-38% longer lifespan than WT controls (56-58).

Igf1-deficient (Igf1−/−) mice showed variable neonatal lethality in several different genetic backgrounds such as 129/Sv mice (10% survival), C57BL/6 x 129/Sv F1 hybrids (16% survival), and MF1 x 129/Sv F1 hybrids (68% survival) (59). The surviving Igf1−/− mice showed 24-40% lower body weights and increased maximum lifespan, but no significant change in mean lifespan (60). Although their body mass was lower than WT (WT 39 g vs Igf1−/− 30 g for male; WT 28 g vs Igf1−/− 17 g for female), there was almost no impact on the size of major organs, including liver (Igf1−/− 1.37 g vs WT 1.39 g), kidney (Igf1−/− 0.21 g vs WT 0.22 g), brain (Igf1−/− 0.44 g vs WT 0.47 g), and heart (Igf1−/− 0.16 g vs WT 0.22 g) (60). The IGFl receptor (IGFR1) deficient (Igflr1−/−) mice show respiratory failure at birth that is 100% lethal (59). Similar to Igf1−/− mice, homozygous insulin receptor (IrsR)-deficient mice suffered from hyperglycemia and died soon after birth (61). Heterozygous IrsR knockout (IrsR+/−) male mice showed heteroin sufficiency, including insulin insensitivity and a 20% extended maximum lifespan, but no significant change in average lifespan (62).
Both inducible liver-specific Igf1 disruption mice (LI-Igf1−/−) (54), and liver-specific Igf1-deficient mice (LID mice) (63) showed a 75% decrease IGFI levels and high GH levels in serum. Igf1 expression was shut off after ~28 days for LI-Igf1−/− mice (54) and after ~10 days in LID mice (63). LI-Igf1−/− female mice, but not male mice, lived 16% longer than WT mice (64), whereas male LID mice exhibited a shortened lifespan (65).

Heterozygous Igf1r−/+ mice exhibited 8% smaller body sizes and ~40% higher serum IGFI level than those of WT mice (4). Increased serum IGFI level is a compensatory response to reduced IGF1 receptor levels. Igf1r−/+ mice also showed a low cellular IGFI signaling activity because of glucose tolerance in the liver (4). Igf1r−/+ mice lived 26% longer than WT controls, 33% longer for female mice and 16% longer for male mice, though the male difference was not statistically significant (4). Another independent study using 16% longer for male mice, though the male difference was not longer than WT controls, 33% longer for female mice and ++ mice was shorter than that of Snell (29-51%), Ames (37-68%), Little (23-25%), or GHR−/− (16-55%) dwarf mice strains. These lifespan differences suggest that there are IRS1-independent, but GH-dependent mechanism for longevity.

IRS2 is known to encode a circulating hormone and functions as an antagonist against IR and IGF1R, increasing insulin resistance (68). Kl−/− mice die early at <100 days of age and show systemic aging phenotypes: growth retardation (small body size, and atrophy of genital organs and thymus), hypokinesis, arteriosclerosis, ectopic calcification in various organs and arterial walls, osteoporosis, and skin atrophy (69). In contrast, Kl overexpression significantly extended lifespan (19-31%) of Kl Tg mice through GH-independent suppression of the IIS pathway (68). Inhibition of IIS by additional genetic interventions, like Kl−/−::IRS1−/−, ameliorated aging-like phenotypes of Kl−/− mice and improved survival (68).

IRS-DEFICIENT MICE

IRS1 and IRS2 are required for the IIS pathway and are evolutionarily-conserved mammalian lifespan regulators (70). IRS1 binds to the IR, activating the PI3K-AKT signaling cascade to regulate glucose metabolism through down-regulation of gluconeogenic enzymes and up-regulation of lipogenic enzymes (71). IRS1−/− mice showed insulin-resistant defects in insulin signaling (72), and lived 14-16% longer than WT littermates (73). The IRS1−/− mice showed small body size, reduced fat mass, and protection from aging-induced insulin resistance (70). Heterozygous IRS1−/+ mice had the same lifespan as WT (70). The lifespan extension seen in the IRS1−/− mice was shorter than that of Snell (29-51%), Ames (37-68%), Little (23-25%), or GHR−/− dwarf mice strains. These lifespan differences suggest that there are IRS1-independent, but GH-dependent mechanism for longevity.

IRS2 is known to play a central role in pancreatic β-cell function (74). IRS2−/− mice die early (maximum 3 months of age) due to their diabetic phenotypes that include defects in hepatic insulin signaling, glucose deregulation, and β-cell failure or apoptosis (70). Several studies have tried to restore the β-cell function of IRS2−/− mice, through mechanisms that included overexpression of transcription factor, Pancreatic and duodenal homeobox 1 (PDX1) to enhance β-cell functions (75), deletion of Protein tyrosine phosphatase, non-receptor type 1 (PTPN1) to reduce insulin sensitivity (76), and reduction of Phosphatase and tensin homolog (PTEN) expression, a potent inhibitor of insulin action (77). These trials achieved some improvements in lifespan, but created additional problems. The lifespan of IRS2−/−::Pdx1 Tg mice increased by 15 months, but they had severe spinal deformities. IRS2−/−::Ptpn1−/− mice had lifespan increases of 8-9 months, but β-cell function deterioration. And IRS2−/−::Pten−/− mice gained 10-12 months of life, but had lymph proliferative disease (78). Heterozygous IRS2−/+ mice showed conflicting lifespan results. Taguchi et al. showed 17% longer (79) and Selman et al. showed no significant change in the lifespan of IRS2−/− mice (70). Selman et al. argued that the WT (C57BL/6) lifespan profile in the study by Taguchi et al. had a significantly different shape compared to other independent WT (C57BL/6) survival curves (80). KO of liver-specific Irs1 (Irs1−/−) and Irs2 (Irs2−/−) in mice exhibited insulin resistance with different meal-timing, after refeeding, and during fasting (81). Interestingly, fasting/refeeding-responsive genes in the liver were significantly down-regulated in Irs1−/− mice, but those genes were not changed in Irs2−/− mice (82). These results suggest that IRS1 is a principal mediator of the regulation of hepatic glucose homeostasis.

Selman et al. measured global hepatic gene expression in female WT and Irs1−/− mice at young (2.6 months old), middle (15 months old), and old (22 months old) ages (70). The results showed up-regulation of several genes in different ages of Irs1−/− mice, including catalase-encoding genes in old age, a glutathione S-transferase gene Gstahl in young age, an excision repair gene Ercc8 at all ages, and a growth regulator Gadd45b at all ages (70). At both young and middle ages, genes for energy metabolism were up-regulated and they were involved in carbohydrate metabolism, acetyl-CoA metabolism, mitochondrial metabolism, including OXPHOS and TCA cycle; and coenzyme and cofactor catabolism. Down-regulated genes at young and middle ages were involved in immune response and antigen processing (70).

FOXO-MEDIATED LONGEVITY GENES

FOXO transcription factors (FoxOs) are inhibitory downstream targets of IIS through activation of AKT, TSC complex subunit 2 (TSC2) and Glycogen synthase kinase 3 (GSK3) (83). The FoxOs are known as evolutionarily conserved anti-aging effectors (84) with broad roles in glucose homeostasis, tumor suppression, autophagy, and resistance to oxidative stress (84,
processes, including leukocyte proliferation, interferon-
activity. Down-regulated DEGs were involved in inflammatory
activity, electron carrier activity, and cytochrome-c oxidase
transcription factors. In muscle, up-regulated DEGs were
involved in negative regulation of RNA metabolism by
genes for fatty acid metabolism. The down-regulated DEGs
biosynthesis of ribosomal small subunits, and included CYP
inflammation were down-regulated. Especially, in liver,
acid metabolism were up-regulated, and DEGs related to
brain (89). Across both muscle and WAT, DEGs related to fatty
were shared from up-regulated DEGs across liver, muscle, and
brain tissues, respectively. Common DEGs of WATs from the three
different locations showed up-regulation of dendritic cell-
expressed genes; and down-regulation of cellular respiration-
related genes, and mitochondrial inner envelope-related
genes. The up-regulation of dendritic cell-expressed genes
might represent an increase of infiltrated dendritic cells in
WATs that correlates with the obese status. Masternak et al.
performed surgical removal of visceral fat in both WT and
GHR−/− mice (92). Visceral fat removal (VFR) from GHR−/−
mice resulted in decreased adiponectin levels, glucose
tolerance, and insulin sensitivity, accompanied by increased
glucose (92). These results suggest that WAT actually has a
beneficial effect on longevity of the GHR−/− mouse. In
contrast, WT mouse with VFR showed improved insulin
sensitivity, reduced body temperature, and decreased
respiration rates; opposite effects, compared to GHR−/−
mice with VFR (92).

Fat-specific insulin receptor knockout (FIR−/−) mice showed
adipocyte-specific insulin resistance, reduced body fat mass,
protection from age- and hyperphagia-associated obesity, and
protection from age-related insulin resistance (93). There was
an interesting difference in adipocyte size in FIR−/− mouse,
compared to WT. Adipocytes isolated from epididymal WAT of
FIR−/− mice divided into two sizes, small (< 75 μm) and
large (> 100 μm), compared to one medium size (75-100 μm)
in WT mice (93). Bluher et al. isolated the small and large
adipocytes from 3-month-old young FIR−/− male mice using
75 μm pore size nylon mesh screen and identified 63 DEGs (P < 0.0001) (94). Later, Katic et al. observed that FIR−/− mouse
showed an increased metabolic rate and higher oxygen
consumption, compared to WT littermates (95). They also
measured WAT transcriptome of FIR−/− male mice at young (6
months old), middle (18 months old), and old (30-36 months
months old), female Lr1−/− mice using an RNA-seq approach. They identified 124
DEGs (FDR < 0.1) in the liver, 185 DEGs in muscle, 111
DEGs in brain, and 344 DEGs in WAT (89). There was no
common DEG across the four different tissues. DEGs from liver,
muscle, and brain tissues shared 5 up-regulated genes encoding
ribosomal proteins, including Ribosomal protein L37a (Rpl37a), Ribosomal protein S26 (Rps26), and Rpl31; and
hemoglobin proteins, including Hemoglobin alpha, adult
chain 1 (Hba-a1), and Hemoglobin beta, adult t chain
(Hbb-bt). DEGs from muscle and WAT had the largest number of
shared genes, including 7 up-regulated genes and 15
down-regulated genes (89). They also found some shared gene
ontology terms across tissues. ECM term was shared in
down-regulated DEGs across all 4 tissues. Organ development
and receptor binding terms were shared from down-regulated
DEGs across muscle, brain, and WAT. Ribosomal protein,
haptoglobin complex, ECM, and antioxidant activity terms
were shared from up-regulated DEGs across liver, muscle, and
brain (89). Across both muscle and WAT, DEGs related to fatty
acid metabolism were up-regulated, and DEGs related to
inflammation were down-regulated. Especially, in liver,
up-regulated DEGs were involved in B cell proliferation and
biosynthesis of ribosomal small subunits, and included CYP
genes for fatty acid metabolism. The down-regulated DEGs
were involved in negative regulation of RNA metabolism by
transcription factors. In muscle, up-regulated DEGs were
involved in mitochondrial functions, including oxidoreductase
activity, electron carrier activity, and cytochrome-c oxidase
activity. Down-regulated DEGs were involved in inflammatory
processes, including leukocyte proliferation, interferon-γ
response, and serine-type endopeptidase inhibition. In brain,
up-regulated DEGs were involved in regulation of adenylate
cyclase and G-protein coupled receptor signaling, and
down-regulated DEGs were involved in morphogenesis and
angio genesis. These results indicate that Lr1−/− mice have
tissue-specific longevity mechanisms.

Fat-specific reduction of GH-IIS axis

Ames, Snell, and GHR−/− dwarf mice showed an obese
phenotype due to their high capacity for lipid storage and
activation of pre-adipocyte differentiation (90). Stout et al.
measured transcriptomes from brown adipose tissue (BAT) and
several WATs at different locations including inguinal,
epididymal and perirenal fat from GHR−/− mouse (91). They
found opposite gene expression trends between WATs and
BAT (91). In BAT, 252 DEGs (FDR < 0.05 and FC > 1.5)
were identified. Up-regulated DEGs were involved in several
metabolic processes including organic acid metabolism,
oxidation-reduction process, cholesterol biosynthesis, and
lipid and acetyl-CoA metabolism. Down-regulated DEGs were
involved in immune and inflammation, including immune
system regulation, innate immune response, inflammation
response, and wound healing. In WATs, 346, 319, and 192
DEGs were identified in inguinal, perirenal, and epididymal fat
tissues, respectively. Common DEGs of WATs from the three
different locations showed up-regulation of dendritic cell-
expressed genes; and down-regulation of cellular respiration-
related genes, and mitochondrial inner envelope-related
genes. The up-regulation of dendritic cell-expressed genes
might represent an increase of infiltrated dendritic cells in
WATs that correlates with the obese status. Masternak et al.
performed surgical removal of visceral fat in both WT and
GHR−/− mice (92). Visceral fat removal (VFR) from GHR−/−
mice resulted in decreased adiponectin levels, glucose
tolerance, and insulin sensitivity, accompanied by increased
glucose (92). These results suggest that WAT actually has a
beneficial effect on longevity of the GHR−/− mouse. In
contrast, WT mouse with VFR showed improved insulin
sensitivity, reduced body temperature, and decreased
respiration rates; opposite effects, compared to GHR−/−
mice with VFR (92).
old ages. The transcriptome data showed age-associated up-regulation of genes related to mitochondria, including OXPHOS and β-oxidation; and age-associated down-regulation of genes related to defense, external stimuli response, and protein prenylation (95). These results indicate that activated mitochondrial function and its maintenance during the aging process may be key mechanisms for the longevity of FIR−/− mice.

**Brain-specific reduction of IIS**

As mentioned previously, the Igf1r−/− mice were lethal because of postnatal respiratory failure (59). Kappeler et al. reported that brain (specifically, hypothalamic)-specific Igf1r heterogenic KO (bIgf1R−/−) mice lived 13% longer than WT mice (96). The bIgf1R−/− mouse model showed ~10% growth retardation, and increases in blood lipid, cholesterol, and free fatty acid levels at young ages (10 months old) (96). Similar to the Gh−/− deficient mice (Snell, Ames and Little), bIgf1R−/− mice showed small pituitary glands, low GH levels, and increased body fat mass (96).

Brain-specific Irs2−/− (bIrs2−/−) and bIrs2−/− mice showed lifespan extension by 18% and 14%, respectively (79). During the aging process, these mice showed hyperinsulinaemia and insulin resistance, as well as high glucose oxidation, and stable superoxide dismutase 2 (SOD2) levels in the hypothalamus, with stable diurnal rhythm (79). These results indicate that the metabolic rate, but not the obese state or insulin sensitivity might be associated with longevity. Sadagurski et al. reported that genetic intervention to reduce IRS2 signaling decreased incidence of age-associated Huntington disease (HD) (97). These results suggest that because brain-specific IRS2 reduction decreased incidence of neurodegenerative diseases, it could lead to longevity.

**Heart-specific Igf overexpression**

In contrast to the aforementioned studies, Li and Ren argued that aging-associated decreases of circulating IGF1 stimulates cardiac aging. They reported that cardiac-specific Igf1 (cligf1) Tg male mice showed a 60-80% increase in plasma IGF1 levels and extended their lifespan by 23% (98). cligf1 Tg mice exhibited improved cardiomyocyte function including increased Ca2+ homeostasis, reduction of protein damage, and decreased apoptosis (98). Indeed, long-lived Ames dwarf mice showed impairment of cardiac excitation-contraction coupling, compared to WT mice (99). Overall, these results suggest that the autocrine/paracrine role of IGF1 is important to cardiac-specific anti-aging effects.

**mTORC1- AND MYC-REDUCED MICE**

Both IIS and mechanistic target of rapamycin (mTOR) pathways could activate ribosomal protein S6 kinase 1 (S6K1), a regulator of growth and metabolism through activation of protein synthesis (100). Although male S6K1−/− mouse showed a similar lifespan to WT, female S6K1−/− mouse showed a 20% longer lifespan than WT. Other phenotypes of female S6K1−/− mice included lean and small body size, and improved insulin sensitivity (101). Interestingly, their total circulating IGF1, pituitary GH, TSH, and PRL levels were not changed compared to WT (101). Lamming et al. reported that mTOR and mLST8 double heterozygous (mtor−/−::mlst8−/−) female mice showed normal body weight and maintained insulin sensitivity (102). And mtor−/−::mlst8−/− female mice showed decreased mTORC1 activity, but not mTORC2, with a 14% extended lifespan (102). Although both S6K1−/− and mtor−/−::mlst8−/− mice showed female-specific longevity, they showed different phenotypes. These results indicate that the small body size and improved insulin sensitivity in S6K1−/− mouse are independent changes, compared to mTORC1-mediated longevity.

Sehlman et al. measured transcriptome in liver, skeletal muscle and WAT of young (10 months old) S6K1−/− female mice (101). They identified 1,843 DEGs (q-value < 0.01) in the liver, 2,309 DEGs in muscle, and 1,970 DEGs in WAT. Across these three tissues, DEGs related to adenosine monophosphate-activated protein kinase (AMPK)-mediated signaling were commonly up-regulated.

p66Shc, an isoform of SHC-transforming protein 1, binds to both IRS1 and S6 kinase and can bridge the two signalings (103). p66Shc−/− and p66Shc+/− mice showed 28% and 7% increased median lifespan, respectively (104). The p66Shc−/− mouse showed less ROS production, high oxidative stress resistance, and prevention of obesity (104).

Tomilov et al. measured transcriptome in liver, spleen, lung, WATs (retroperitoneal and epididymal), and peritoneal macrophages from young p66Shc−/− mice (3 months old males, and 12 months old males and females) (105). They found that commonly down-regulated DEGs (P < 0.05) were enriched in PI3K signaling, antigen processing, chronic myeloid leukemia, adipokine signaling, anti-apoptosis, and heme transcripts by gene ontology analysis (105). During phagocytosis, phagocytes, including neutrophils, eosinophils and macrophages exhibit an intense consumption of oxygen for NADPH oxidase (PHOX), in a process called a respiratory burst (106). In a comparison of peritoneal macrophages, p66Shc−/− mice showed 31% less PHOX activity and 40% less production of PHOX-dependent superoxide than WT mice (105).

Myc transcription factor, known as a protooncogene regulates various downstream functions, including energy metabolism, ribosome biogenesis, cell cycle, apoptosis, differentiation, and stem cell maintenance (107). Recently, Hofmann et al. reported that heterozygous Myc−/− mice showed a 15% longer lifespan than WT mice, while Myc null mice resulted in an embryonic lethal phenotype (108). Myc−/− mice showed 15-20% less body mass, 56-64% lower serum IGF1 levels, higher metabolic rates, and higher AMP levels in liver, whereas there was no difference in adipose tissue mass, reproductive ability, or
incidence of deaths due to cancer, compared to WT mice (108).

Hofmann et al. (2015) measured transcriptome in young (5 months of age) and old (24 months of age) Myc−/− male mice and identified 307, 160 and 412 DEGs (FDR < 0.05 and FC > 1.5) in the liver, skeletal muscle, and gonadal WAT, respectively, compared to those of WT mice (108). The altered DEGs showed tissue-specific functions without a common DEG across the three tissues. In liver, down-regulated DEGs at old age were involved in cholesterol biosynthesis, and Myc−/− mice were protected from age-associated enlargement of hepatic lipid droplets (108). Comparing hepatic DEGs from Myc−/− mice to long-lived Snell, Little, and GHR−/− mice, the DEGs for xenobiotic metabolism enzymes, including CYP genes, Fmo3, Fmo4, Hao2, Mt1, Mt2, and P450 (cytochrome) oxidoreductase (Por) were commonly up-regulated, but the fold changes were orders of magnitudes smaller in Myc−/− mice (108). In addition, Myc−/− mice showed decreases in S6 kinase and AKT activities in both liver and muscle, an increase of AMPK in liver, and decreased serum IGF1 levels, whereas none of the genes related to these pathway components were identified as DEGs (108). Based on these observations, the authors hypothesized that the reduced available energy in the liver of Myc−/− mice activates AMPK, and then reduces mTOR and S6 kinase activities (108), promoting longevity.

CONCLUDING REMARKS

GH signal-deficient mice, including Snell, Ames, Little, and Fgf21 Tg dwarf mice, showed increased lifespans and smaller body masses than WT mice. Therefore, body size was strongly dependent on GH action. This consistent trend suggests an inverse correlation between size and lifespan (109). However, small size can not be used as a general indicator of longevity, because Kl Tg, Irs2−/− mice had high body fat. These results indicate brain-mediated endocrinological control of body fat and the IGF1 feedback loop. However, excess weight and obesity are known risk factors of aging and cause critical diseases, including diabetes and heart failure (110). Indeed, Ll-Igf1−/−, Fir−/−, Irs1−/−, S6K1−/−, and p66Shc−/− mice had normal body masses like WT mice, but showed longer lifespans than WT. In addition, GHA Tg mice had normal lifespans like WT mice, and Kl−/− and Irs2−/− mice showing dramatically shorter lifespans also had a dwarfism phenotype.

Snell, Ames, Little, and GHR−/− mice exhibited obesity, caused by loss of lipolytic and anti-lipogenic activities of GH. Especially, long-lived biGF1R−/−, blrs2−/−, and blrs2−/− mice had high body fat. These results indicate brain-mediated endocrinological control of body fat and the IGF1 feedback loop. However, excess weight and obesity are known risk factors of aging and cause critical diseases, including diabetes and heart failure (110). Indeed, Ll-Igf1−/−, Fir−/−, Irs1−/−, S6K1−/−, and p66Shc−/− mice showed less body fat than WT animals. In contrast, bGH Tg mice producing excess GH had lean bodies, but shortened lifespans. Surgical removal of visceral fat in GH−/− mice decreased the fat-induced beneficial effects (92). Therefore, under the different endocrine circumstances, regardless of the body fat mass, adipose tissue itself contributes effects beneficial to longevity.

High insulin sensitivity could be associated with improved health. Long-lived GH signal-deficient mice, as well as Fir−/− and S6K1−/− mice, showed high insulin sensitivity. However, some long-lived mice with a mutation in IIS components, including Ll-Igf1−/−, Igf1r−/−, biGF1R−/−, and Irs1−/−, as well as the Kl Tg mice displayed insulin resistance. In the case of systemic Irs2 deficiency, Irs2−/− mice had diabetes, whereas brain-specific mutant blrs2−/− mice showed both insulin resistance and longevity. Interestingly, R62::Irs2−/−::Irs2BTg mice, genetically modified to be Irs2−/− heterozygous except in β cells, showed a slow Huntington disease (HD) progression (97). In addition, insulin resistant (e.g., IR−/−) male mice showed a 20% extended maximum lifespan, but high insulin sensitivity mice, including PTP-1B−/− and PGC-1α Tg displayed shortened or similar lifespans compared to WT mice, respectively (62). It is clear that manipulation of insulin sensing signaling produces beneficial effects on longevity, however, either impaired or hyper-sensitive insulin signaling can lead to shortened lifespans.

Snell, Ames, Little, GHR−/− and biGF1R−/− mice showed both high-stress resistance and less tumor incidence. Papp−/− mice also showed less tumor incidence, and Kl Tg, Igf1r−/−, and p66Shc−/− mice showed high-stress resistance. Haploid DEGs of Snell, Ames, Little, and GHR−/− mice showed up-regulation of DEGs for xenobiotic metabolism (e.g., Fmo3, Cyp5a, Gsts, and Sulfotransferases) and oxidative stress response (e.g., Hao2 and Hao3), representing improved stress response and DNA damage repair (111) (88). Genetically manipulated GF1R−/− mice had normal body size, showed a slow Huntington disease (HD) progression, and PGC-1α Tg dwarf mice showed decreases in S6, bIrs2−/−, and bIGF1R−/− mice had diabetes, whereas Kl−/− mice had normal lifespans like WT mice, and Kl−/− and Irs2−/− mice showing dramatically shorter lifespans also had a dwarfism phenotype.

Snell, Ames, Little, and GHR−/− mice exhibited obesity, caused by loss of lipolytic and anti-lipogenic activities of GH. Especially, long-lived biGF1R−/−, blrs2−/−, and blrs2−/− mice had high body fat. These results indicate brain-mediated endocrinological control of body fat and the IGF1 feedback loop. However, excess weight and obesity are known risk factors of aging and cause critical diseases, including diabetes and heart failure (110). Indeed, Ll-Igf1−/−, Fir−/−, Irs1−/−, S6K1−/−, and p66Shc−/− mice showed less body fat than WT animals. In contrast, bGH Tg mice producing excess GH had lean bodies, but shortened lifespans. Surgical removal of visceral fat in GH−/− mice decreased the fat-induced beneficial effects (92). Therefore, under the different endocrine circumstances, regardless of the body fat mass, adipose tissue itself contributes effects beneficial to longevity.
pleiotropy (SAP) (112). STAT5-mediated liver gene expression analysis showed altered genes in xenobiotic metabolism (e.g., CYPs, GSTs, and sulfotransferases), oxidative stress response, and serine protease inhibitors. They overlap with the aforementioned longevity-associated liver gene expression data. In particular, Hsd3b5 encoding a ketosteroid reductase for steroid hormone biosynthesis, including testosterone was commonly down-regulated in Snell, Ames, Little, GHR−/−, and Fgf21 Tg mice. The expression of Hsd3b5 was associated with activation of GHR-STAT5 signaling, suggesting testosterone inactivation might contribute to the female-biased longevity.

On the other hand, Myc−/− mice showed up-regulated DEGs for xenobiotic metabolism and inhibition of mTOR and S6 kinases, however their tumor incidence was similar to WT mice (108). In addition, Ki Tg, bgFR1−/−, and Iris−/− mice showed similar lifespan extension in both males and females. Therefore, more work is needed to elucidate factors contributing to the lifespan of these mice.

ACKNOWLEDGEMENTS

This work was carried out with the support of Bio and Medical Technology Development Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2017R1D1A1A020 19355).

CONFLICTS OF INTEREST

The authors have no conflicting interests.

REFERENCES

1. Barbieri M, Bonafe M, Franceschi C and Paolisso G (2003) Insulin/IGF-I-signaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. Am J Physiol Endocrinol Metab 285, E1064-1071
2. Fontana L, Partridge L and Longo VD (2010) Extending healthy life span—from yeast to humans. Science 328, 321-326
3. Hwangbo DS, Gershman B, Tu MP, Palmer M and Tatar M (2004) Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 429, 562-566
4. Holzenberger M, Dupont J, Ducos B et al (2003) IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421, 182-187
5. Bonafe M and Olivieri F (2009) Genetic polymorphism in long-lived people: for the presence of an insulin/IGF-pathway-dependent network affecting human longevity. Mol Cell Endocrinol 299, 118-123
6. Junnilla RK, List EO, Berryman DE, Murrey JW and Kopchick JJ (2013) The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol 9, 366-376
7. Zhang J and Liu F (2014) Tissue-specific insulin signaling in the regulation of metabolism and aging. IUBMB Life 66, 485-495
8. Rask-Madsen C and Kahn CR (2012) Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler Thromb Vasc Biol 32, 2052-2059
9. Florey K, Papacostantinou J, Miller RA and Harrison DE (2001) Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc Natl Acad Sci U S A 98, 6736-6741
10. Florey K, Papacostantinou J and Harrison DE (2002) The Snell dwarf mutation Pit1(dw) can increase life span in mice. Mech Ageing Dev 123, 121-130
11. Lin L, Hale SP and Schimmel P (1996) Aminoacylation error correction. Nature 384, 33-34
12. Zhou Y, Xu BC, Maheshwari HG et al (1997) A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci U S A 94, 13215-13220
13. Coschigano KT, Clemmons D, Bellush LL and Kopchick JJ (2000) Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 141, 2608-2613
14. Chen WY, Wight DC, Mehta W, Wagner TE and Kopchick JJ (1991) Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol 5, 1845-1852
15. Chen WY, White ME, Wagner TE and Kopchick JJ (1991) Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology 129, 1402-1408
16. Berryman DE, List EO, Coschigano KT, Behar K, Kim JK and Kopchick JJ (2004) Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF Res 14, 309-318
17. Coschigano KT, Holland AN, Riders ME, List EO, Flyvbjerg A and Kopchick JJ (2003) Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 144, 3799-3810
18. Salminen A, Kaarniranta K and Kauppinen A (2017) Regulation of longevity by FGF21: Interaction between energy metabolism and stress responses. Ageing Res Rev 37, 79-93
19. Kuro-o M (2012) Klotho and betaKlotho. Adv Exp Med Biol 728, 25-40
20. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ and Kliewer SA (2008) Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 8, 77-83
21. Zhang Y, Xie Y, Berglund ED et al (2012) The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife 1, e00065
22. Bartke A (2003) Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice. Neuroendocrinology 78, 210-216
23. Doi T, Striker LJ, Quaife C et al (1988) Progressive glomerulosclerosis develops in transgenic mice...
chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulin-like growth factor-1. Am J Pathol 131, 398-403
24. Yang CW, Striker LJ, Pesce C et al (1993) Glomerulosclerosis and body growth are mediated by different portions of bovine growth hormone. Studies in transgenic mice. Lab Invest 68, 62-70
25. Chanson P and Salenave S (2008) Acrornegaly. Orphanet J Rare Dis 3, 17
26. Clayton PE, Banerjee I, Murray PG and Renehan AG (2011) Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 7, 11-24
27. Dozmorov I, Bartke A and Miller RA (2001) Array-based expression analysis of mouse liver genes: effect of age and of the longevity mutant Prop1df. J Gerontol A Biol Sci Med Sci 56, B72-80
28. Dozmorov I, Galecki A, Chang Y, Krzesicki R, Vergara M and Miller RA (2002) Gene expression profile of long-lived snell dwarf mice. J Gerontol A Biol Sci Med Sci 57, B99-108
29. Amador-Noguez D, Yagi K, Venable S and Darlington G (2004) Gene expression profile of long-lived Ames dwarf mice and Little mice. Aging Cell 3, 423-441
30. Boylston WH, Gerstner A, DeFord JH et al (2004) Altered choleresterogenic and lipogenic transcriptional profile in livers of aging Snell dwarf (Pit1+/-/+) mice. Aging Cell 3, 283-296
31. Tsuchiya T, Dhahbi JM, Cui X, Mote PL, Bartke A and Melner MH (2005) Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev 26, 197-207
32. Amador-Noguez D, Zimmerman J, Venable S and Darlington G (2005) Gender-specific alterations in gene expression and loss of liver sexual dimorphism in the long-lived Ames dwarf mice. Biochem Biophys Res Commun 332, 1086-1100
33. Papacostantinou J, DeFord JH, Gerstner A et al (2005) Hepatic gene and protein expression of primary components of the IGF-I axis in long lived Snell dwarf mice. Mech Ageing Dev 126, 692-704
34. Boylston WH, DeFord JH and Papacostantinou J (2006) Identification of longevity-associated genes in long-lived Snell and Ames dwarf mice. Age (Dordr) 28, 125-144
35. Rossner R, Kaeberlein M and Leiser SF (2017) Flavin-containing monoxygenases in aging and disease: Emerging roles for ancient enzymes. J Biol Chem 292, 11138-11146
36. Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA and Melner MH (2005) Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev 26, 525-582
37. Jones JM, Morrell JC and Gould SJ (2000) Identification and characterization of HAOX1, HAOX2, and HAOX3, three human peroxisomal 2-hydroxy acid oxidases. J Biol Chem 275, 12590-12597
38. Rowland JE, Lichanska AM, Kerr LM et al (2005) In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol Cell Biol 25, 66-77
39. Barclay JL, Nelson CN, Ishikawa M et al (2011) GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology 152, 181-192
40. Chang L, Qi H, Xiao Y et al (2016) Integrated analysis of noncoding RNAs and miRNAs reveals their potential roles in the biological activities of the growth hormone receptor. Growth Horm IGF Res 29, 11-20
41. Swindell WR (2007) Gene expression profiling of long-lived dwarf mice: longevity-associated genes and relationships with diet, gender and aging. BMC Genomics 8, 353
42. Nicola NA and Babin JJ (2015) Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev 26, 533-544
43. Yano H, Readhead C, Nakashima M, Ren SG and Melmed S (1998) Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: neuro-immune-endocrine modulation of pituitary development. Mol Endocrinol 12, 1708-1720
44. Niedernhofer LJ, Garinis GA, Raams A et al (2006) A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444, 1038-1043
45. van der Pluijm J, Garinis GA, Brandt RM et al (2007) Impaired genome maintenance suppresses the growth hormone-insulin-like growth factor 1 axis in mice with Cockayne syndrome. PLoS Biol 5, e2
46. Schumacher B, van der Pluijm J, Moorhouse MJ et al (2008) Delayed and accelerated aging share common longevity assurance mechanisms. PLoS Genet 4, e1000161
47. Jansson JO, Eden S and Isaksson O (1985) Sexual dimorphism in the control of growth hormone secretion. Endocr Rev 6, 128-150
48. MacLeod JN, Pampori NA and Shapiro BH (1991) Sex differences in the ultradian pattern of plasma growth hormone concentrations in mice. J Endocrinol 131, 395-399
49. Mode A and Gustafsson JA (2006) Sex and the liver - a journey through five decades. Drug Metab Rev 38, 197-207
50. Waxman DJ and O’Connor C (2006) Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol 20, 2613-2629
51. Yang X, Schadt EE, Wang S et al (2006) Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res 16, 995-1004
52. Clodfelter KH, Holloway MG, Hodor P, Park SH, Ray WJ and Waxman DJ (2006) Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol Endocrinol 20, 1333-1351
53. Clodfelter KH, Miles GD, Wauthier V et al (2007) Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis. Physiol Genomics 31, 63-74
54. Sjogren K, Liu JL, Blad K et al (1999) Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A 96, 7088-7092
Growth signaling and longevity
Seung-Soo Kim and Cheol-Koo Lee

55. Conover CA (2012) Key questions and answers about pregnancy-associated plasma protein-A. Trends Endocrinol Metab 23, 242-249
56. Conover CA, Bale LK, Overgaard MT et al (2004) Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 131, 1187-1194
57. Conover CA and Bale LK (2007) Loss of pregnancy-associated plasma protein A extends lifespan in mice. Aging Cell 6, 727-729
58. Conover CA, Bale LK, Mader JR, Mason MA, Keenan KP and Marler RJ (2010) Longevity and age-related pathology of mice deficient in pregnancy-associated plasma protein-A. J Gerontol A Biol Sci Med Sci 65, 590-599
59. Liu JP, Baker J, Perkins AS, Robertson EJ and Estrada A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75, 59-72
60. Lorenzini A, Salmen AB, Lerner C et al (2014) Mice producing reduced levels of insulin-like growth factor type 1 display an increase in maximum, but not mean, life span. J Gerontol A Biol Sci Med Sci 69, 410-419
61. Accili D, Drago J, Lee JI et al (1996) Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 12, 106-109
62. Nelson JF, Strong R, Bokov A, Diaz V and Ward W (2012) Probing the relationship between insulin sensitivity and longevity using genetically modified mice. J Gerontol A Biol Sci Med Sci 67, 1332-1338
63. Yakar S, Liu JT, Stamm B et al (1999) Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 96, 7324-7329
64. Svensson J, Sjogren K, Faldt J et al (2011) Liver-derived IGF-I regulates mean life span in mice. PLoS One 6, e22640
65. Novosyadlyy R and Leroith D (2012) Insulin-like growth factors and insulin: at the crossroad between tumor development and longevity. J Gerontol A Biol Sci Med Sci 67, 640-651
66. Bokov AF, Garg N, Ikeda Y et al (2011) Does reduced IGF-1R signaling in Igf1r +/- mice alter aging? PLoS One 6, e26891
67. Ladiges W, Van Remmen H, Strong R et al (2009) Lifespan extension in genetically modified mice. Aging Cell 8, 346-352
68. Kuros H, Yamamoto M, Clark JD et al (2005) Suppression of aging in mice by the hormone Klotho. Science 309, 1829-1833
69. Kuro-o M, Matsumura Y, Aizawa H et al (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390, 45-51
70. Selman C, Linstead S, Choudhary AI et al (2008) Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J 22, 807-818
71. Peng J and He L (2018) IRS posttranslational modifications in regulating insulin signaling. J Mol Endocrinol 60, R1-R8
72. Previs SF, Withers DJ, Ren JM, White MF and Shulman GI (2000) Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem 275, 38990-38994
73. Selman C, Partridge L and Withers DJ (2011) Replication of extended lifespan phenotype in mice with deletion of insulin receptor substrate 1. PLoS One 6, e16144
74. Withers DJ, Gutierrez JS, Towery H et al (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900-904
75. Kushner JA, Ye J, Schubert M et al (2002) Pdx1 restores beta cell function in Ins2 knockout mice. J Clin Invest 109, 1193-1201
76. Kushner JA, Haj FG, Klamann LD et al (2004) Islet-sparing effects of protein tyrosine phosphatase-1b deficiency delays onset of diabetes in IRS2 knockout mice. Diabetes 53, 61-66
77. Kushner JA, Simpson L, Wartschow LM et al (2005) Phosphatase and tensin homolog regulation of islet growth and glucose homeostasis. J Biol Chem 280, 39388-39393
78. Taguchi A and White MF (2008) Insulin-like signaling 1 nutrient homeostasis, and life span. Annu Rev Physiol 70, 191-212
79. Taguchi A, Wartschow LM and White MF (2007) Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317, 369-372
80. Selman C, Lingard S, Gens D, Partridge L and Withers DJ (2008) Comment on "Brain IRS2 signaling coordinates life span and nutrient homeostasis". Science 320, 1012; author reply 1012
81. Kubota N, Kubota T, Itoh S et al (2008) Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab 8, 49-64
82. Guo S, Capps KD, Dong X et al (2009) The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 29, 5070-5083
83. Brunet A, Bonni A, Zigmond MJ et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868
84. Martins R, Lithgow GI and Link W (2016) Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. Aging Cell 15, 196-207
85. Hannenhalli S and Kaestner KH (2009) The evolution of Fox genes and their role in development and disease. Nat Rev Genet 10, 233-240
86. Shimokawa I, Komatsu T, Hayashi N et al (2015) The life-extending effect of dietary restriction requires Fxo3 in mice. Aging Cell 14, 707-709
87. Boehm AM, Khalturin K, Anton-Erxleben F et al (2012) FOXO is a critical regulator of stem cell maintenance in immortal Hydra. Proc Natl Acad Sci U S A 109, 19697-19702
88. Webb AE, Kundaje A and Brunet A (2016) Characterization of the direct targets of FOXO transcription factors throughout evolution. Aging Cell 15, 673-685
89. Page MM, Schuster EF, Mudaliar M, Herzyk P, Withers DJ and Selman C (2018) Common and unique transcriptional responses to dietary restriction and loss of
insulin receptor substrate 1 (IRS1) in mice. Aging (Albany NY) 10, 1027-1052
90. Stout MB, Tchkonia T, Pirtskhalava T et al (2014) Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice. Aging (Albany NY) 6, 575-586
91. Stout MB, Swindell WX, Zhi X et al (2015) Transcriptome profiling reveals divergent expression shifts in brown and white adipose tissue from long-lived GHRKO mice. Oncotarget 6, 26702-26715
92. Masternak MM, Bartke A, Wang F et al (2012) Metabolic effects of intra-abdominal fat in GHRKO mice. Aging Cell 11, 73-81
93. Bluher M, Michael MD, Peroni OD et al (2002) Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 3, 25-38
94. Bluher M, Patti ME, Gesta S, Kahn BB and Kahn CR (2004) Intrinsic heterogeneity in adipose tissue of fat-specific insulin receptor knock-out mice is associated with differences in patterns of gene expression. J Biol Chem 279, 31891-31901
95. Katic M, Kennedy AR, Leykin I et al (2007) Mitochondrial gene expression and increased oxidative metabolism: role in increased lifespan of fat-specific insulin receptor knock-out mice. Aging Cell 6, 827-839
96. Kappeler L, De Magalhaes Filho C, Dupont J et al (2008) Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism. PloS Biol 6, e254
97. Sadagurski M, Cheng Z, Rozzo A et al (2011) IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J Clin Invest 121, 4070-4081
98. Li Q and Ren J (2007) Influence of cardiac-specific overexpression of insulin-like growth factor I on lifespan and aging-associated changes in cardiac intracellular Ca2+ homeostasis, protein damage and apoptotic protein expression. Aging Cell 6, 799-806
99. Ren J and Brown-Borg HM (2002) Impaired cardiac excitation-contraction coupling in ventricular myocytes from Ames dwarf mice with IGF-I deficiency. Growth Horm IGF Res 12, 99-105
100. Um SH, D’Alessio D and Thomas G (2006) Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 3, 393-402
101. Selman C, Tullet JM, Wieser D et al (2009) Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326, 140-144
102. Lamming DW, Ye L, Katajisto P et al (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335, 1638-1643
103. Ranieri SC, Fusco S, Panieri E et al (2010) Mammalian life-span determinant p66shc mediates obesity-induced insulin resistance. Proc Natl Acad Sci U S A 107, 13420-13425
104. Migliaccio E, Giorgio M, Mele S et al (1999) The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402, 309-313
105. Tomilov AA, Bicocca V, Schoenfeld RA et al (2010) Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice. J Biol Chem 285, 1153-1165
106. Wentjes FB and Segal AW (1995) NADPH oxidase and the respiratory burst. Semin Cell Biol 6, 357-365
107. Dang CV (2012) MYC on the path to cancer. Cell 149, 22-35
108. Hofmann JW, Zhao X, De Cecco M et al (2015) Reduced expression of MYC increases longevity and enhances healthspan. Cell 160, 477-488
109. Bartke A (2012) Healthy aging: is smaller better? - a mini-review. Gerontology 58, 337-343
110. Wang S and Ren J (2018) Obesity Paradox in Aging: From Prevalence to Pathophysiology. Prog Cardiovasc Dis 61, 182-189
111. Murakami S (2006) Stress resistance in long-lived mouse models. Exp Gerontol 41, 1014-1019
112. Tower J (2017) Sex-Specific Gene Expression and Life Span Regulation. Trends Endocrinol Metab 28, 735-747